Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/9948
Title: | HIV-1 Transmitted Drug Resistance Mutations in Newly Diagnosed Antiretroviral-Naive Patients in Turkey | Authors: | Sayan, M. Sargin, F. Inan, D. Sevgi, D.Y. Celikbas, A.K. Yasar, K. Kaptan, F. |
Keywords: | antivirus agent nonnucleoside reverse transcriptase inhibitor RNA directed DNA polymerase inhibitor thymidine derivative anti human immunodeficiency virus agent Human immunodeficiency virus proteinase Human immunodeficiency virus proteinase inhibitor RNA directed DNA polymerase virus RNA antiviral resistance Article child cohort analysis female human Human immunodeficiency virus 1 Human immunodeficiency virus 1 infection Human immunodeficiency virus infected patient major clinical study male preschool child prevalence priority journal Turkey (republic) virus mutation virus transmission world health organization adult CD4 lymphocyte count drug effects gene expression genetics growth, development and aging Human immunodeficiency virus infection metabolism mutation transmission Adult Anti-HIV Agents CD4 Lymphocyte Count Drug Resistance, Viral Female Gene Expression HIV Infections HIV Protease HIV Protease Inhibitors HIV Reverse Transcriptase HIV-1 Humans Male Mutation Prevalence Reverse Transcriptase Inhibitors RNA, Viral Turkey |
Publisher: | Mary Ann Liebert Inc. | Abstract: | HIV-1 replication is rapid and highly error-prone. Transmission of a drug-resistant HIV-1 strain is possible and occurs within the HIV-1-infected population. In this study, we aimed to determine the prevalence of transmitted drug resistance mutations (TDRMs) in 1,306 newly diagnosed untreated HIV-1-infected patients from 21 cities across six regions of Turkey between 2010 and 2015. TDRMs were identified according to the criteria provided by the World Health Organization's 2009 list of surveillance drug resistance mutations. The HIV-1 TDRM prevalence was 10.1% (133/1,306) in Turkey. Primary drug resistance mutations (K65R, M184V) and thymidine analogue-associated mutations (TAMs) were evaluated together as nucleos(t)ide reverse transcriptase inhibitor (NRTI) mutations. NRTI TDRMs were found in 8.1% (107/1,306) of patients. However, TAMs were divided into three categories and M41L, L210W, and T215Y mutations were found for TAM1 in 97 (7.4%) patients, D67N, K70R, K219E/Q/N/R, T215F, and T215C/D/S mutations were detected for TAM2 in 52 (3.9%) patients, and M41L + K219N and M41L + T215C/D/S mutations were detected for the TAM1 + TAM2 profile in 22 (1.7%) patients, respectively. Nonnucleoside reverse transcriptase inhibitor-associated TDRMs were detected in 3.3% (44/1,306) of patients (L100I, K101E/P, K103N/S, V179F, Y188H/L/M, Y181I/C, and G190A/E/S) and TDRMs to protease inhibitors were detected in 2.3% (30/1,306) of patients (M46L, I50V, I54V, Q58E, L76V, V82A/C/L/T, N83D, I84V, and L90M). In conclusion, long-term and large-scale monitoring of regional levels of HIV-1 TDRMs informs treatment guidelines and provides feedback on the success of HIV-1 prevention and treatment efforts. © Copyright 2016, Mary Ann Liebert, Inc. 2016. | URI: | https://hdl.handle.net/11499/9948 https://doi.org/10.1089/aid.2015.0110 |
ISSN: | 0889-2229 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Files in This Item:
File | Size | Format | |
---|---|---|---|
selda sayın kutlu.pdf | 149.1 kB | Adobe PDF | View/Open |
CORE Recommender
SCOPUSTM
Citations
20
checked on Nov 30, 2024
WEB OF SCIENCETM
Citations
19
checked on Dec 4, 2024
Page view(s)
32
checked on Aug 24, 2024
Download(s)
22
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.